Granite Bio is developing a new product line for the immune-mediated rheumatoid arthritis (RA) market.
Public source
Company
Granite Bio
- Industry
- Biotechnology Research
- Location
- Basel, CH
- Company size
- 11–50 employees
About Granite Bio
Targeting fundamentals of inflammation, autoimmunity and fibrosis
See moreLatest activity
Latest activity from Granite Bio
5 signals
Research & Knowledge
Granite Bio is developing a new extracellular matrix modification technology.
Research & Knowledge
Granite Bio's Dominik Hartl, MD presented a paper on interleukin-33 and its receptor multifaceted activity at the 2026 Annual Meeting of the American Society of Clinical Oncology
Presence & Recognition
Granite Bio employee Dominik Hartl has been featured in a LinkedIn post.
Discover more
Similar signals
Similar public activity from other companies.
Strategy & Corporate Development
Merida Biosciences
Merida Biosciences entered into a definitive agreement to be acquired by Eli Lilly and Company to advance treatments for serious autoimmune and allergic diseases.
Strategy & Corporate Development
MitoRx Therapeutics
MitoRx Therapeutics decided to pivot away from a rare disease indication in response to partner and buyer feedback, and towards high-risk obesity.
Strategy & Corporate Development
Lindus
Lindus Therapeutics is in-licensing external assets and developing them through to value inflection points.
Strategy & Corporate Development
Attune Biotech
Attune Biotech is entering an important phase of growth after achieving multiple regulatory and clinical milestones.
Strategy & Corporate Development
GRI Bio, Inc.